Gallbladder Cancer Recurrence: What to Ask

The NCI summary groups gallbladder cancer that cannot be removed, has spread, or has come back into one bucket. It says plainly that these are not curable.

It says two more things in the same breath. Symptoms can be improved a great deal by relieving a blocked bile duct. And a few people have slow-growing tumors and live several years.

Both halves are true at once. Ask your team which half describes you.

NCI treats a blocked bile duct as its own problem to fix. When itching and poor liver function outweigh other symptoms, draining the bile is warranted.

The preferred methods are a drain placed through the skin or a stent placed by endoscopy. Surgical bypass is used when neither works.

If you already have a stent, ask what a blockage or infection would feel like and who to call at 2am.

Cisplatin with gemcitabine is the reference chemotherapy backbone here. NCI says adding a checkpoint inhibitor, either durvalumab or pembrolizumab, has become standard first-line care.

That came from two trials in biliary tract cancer. In TOPAZ-1, 685 people received chemotherapy with durvalumab or with placebo. Median overall survival was 12.9 months in the durvalumab group and 11.3 months in the placebo group.

NCI lists alternatives too: gemcitabine with capecitabine, GEMOX and XELOX. It also says every patient should consider a trial.

NCI says anyone with unresectable, spread or recurrent disease who has not had a checkpoint inhibitor should be tested for mismatch repair loss or high microsatellite instability. A positive result opens the door to pembrolizumab.

It also names three further targets worth looking for: IDH1 changes, FGFR2 gene fusions and HER2. NCI frames these as routes into trials, and notes that drugs approved for bile duct cancer could reasonably be used for the right patient.

NCI mentions palliative radiation after the bile is draining. It is aimed at symptoms in one place rather than at the whole disease.

• Is this something a surgeon could still remove, or not?
• Does my bile duct need draining before anything else?
• Have I been tested for mismatch repair or high microsatellite instability?
• Was my tumor checked for IDH1, FGFR2 or HER2?
• Am I well enough for cisplatin and gemcitabine again?
• Would adding durvalumab or pembrolizumab apply to me?
• Which trial is open, and does timing affect whether I qualify?

Ask what the goal is now. Ask what would make you call before the next appointment.

• Call 911 or go to an emergency department if you have fever and chills together with yellow skin and pain in the upper right of your abdomen, especially with confusion or feeling faint. That combination points to an infected, blocked bile duct, which needs treating at once. Go in without delay too if your temperature reads 100.4°F (38°C) or higher while you are on chemotherapy, the figure CDC uses. CDC classes a fever during chemotherapy as an emergency, since the drugs leave few white cells to contain an infection.
• Call your care team the same day if your skin or eyes turn yellow, your urine darkens, your stools turn pale, or itching starts or gets worse. Also call the same day if a biliary drain stops draining, leaks, or comes loose.
• Call your care team within a day or two if upper abdominal pain is new or worse, spreads to your back or shoulder blade, or you cannot keep food down.

Cancer Staging and Biomarker Testing explain the terms that come up most when gallbladder cancer comes back. Clinical Trial vs Standard Treatment, Palliative Care, and Questions to Ask Your Doctor cover the decisions that follow a gallbladder cancer recurrence.

These questions were drawn from current patient guidance for gallbladder cancer:

• NCI PDQ - Gallbladder Cancer Treatment (Patient Version)
• NCI PDQ - Gallbladder Cancer Treatment (Health Professional Version)
• MedlinePlus — Cholangitis
• NCI — Infection and neutropenia during cancer treatment